AbbVie, Eli Lilly, WuXi PharmaTech, Johnson & Johnson and Alexandria Real Estate Equities are among the investors in the genomic cancer treatment developer.
US-based cancer therapy developer ApoGen Biotechnologies has secured $7m in a series A round featuring pharmaceutical companies AbbVie, Eli Lilly, WuXi PharmaTech and Johnson & Johnson.
Alexandria Venture Investments, part of real estate developer Alexandria Real Estate Equities, also took part in the round, as did investment firm Accelerator Corporation, Arch Venture Partners, Watson Fund and Washington Research Foundation subsidiary WRF Capital.
ApoGen is developing drug therapies that will disrupt the development of drug resistance by cancer cells by targeting…